Annovis Bio Inc（ANVS）资讯与事件ANVSAnnovis Bio Inc

Canaccord Acts as Sole Underwriter for Offering Priced Below $1.21

Canaccord is acting as sole book running manager for the offering. The deal priced below last closing price of $1.21.

Annovis Bio Notified by NYSE of Non-Compliance with Listing Standards

Annovis Bio announced that it received notice from the NYSE that it is no longer in compliance with the NYSE continued listing standards set forth in Section 802.01B of the NYSE's Listed Company Manual due to the fact that the company's average market capitalization over a consecutive 30 trading-day period was less than $50M while its stockholders' equity was less than $50M.

Annovis Bio Collaborates with Weave Bio for NDA Support

Annovis Bio announced a collaboration with Weave Bio, an AI platform for regulatory content and knowledge management, in support of the planned New Drug Application, NDA, for buntanetap. Under the collaboration, Annovis will use Weave for drafting, reviewing and managing the NDA documents as the Company heads toward a 6-month top-line data readout from the pivotal Phase 3 AD trial - the data that will form the basis of the submission. Annovis' regulatory and clinical teams will retain full responsibility for content, verification and final approval of every document submitted to the U.S. Food and Drug Administration.